Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC) Meeting Abstract


Authors: Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; Scher, H. I.; Morris, M. J.
Abstract Title: Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)
Meeting Title: 49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 15 Suppl.
Meeting Dates: 2013 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-05-20
Language: English
ACCESSION: WOS:000335419602013
PROVIDER: wos
DOI: 10.1200/jco.2013.31.15_suppl.5090
Notes: Meeting Abstract: 5090 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Josef J Fox
    71 Fox
  2. Susan Slovin
    254 Slovin
  3. Michael Morris
    577 Morris
  4. Karen Anne Autio
    119 Autio
  5. Heiko Schoder
    543 Schoder
  6. Dana Elizabeth Rathkopf
    272 Rathkopf
  7. John Laurence Humm
    433 Humm
  8. Steven M Larson
    958 Larson
  9. Howard Scher
    1130 Scher
  10. Daniel C Danila
    154 Danila
  11. Eric C Haupt
    8 Haupt